News & Media

Hemostemix Announces New EU Patent Grant

CALGARY, Alberta, May 23, 2018 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has been granted a new patent in the European Union (the “EU”) for its patent entitled “Regulating Stem Cells”.

The EU Patent and Trademark Office has granted patent number EP1833962 “Regulating Stem Cells”, which is part of a family of patents the Company has in its extensive patent portfolio. This patent has previously been granted in Canada and the United States and covers a method for generating therapeutic precursor cell products, including the Company’s lead product ACP-01. These precursor cells are generated from a core population of cells named “Synergetic Cell Population” (“SCP”) cells. SCP cells have the capacity to grow new blood vessels, and with Company’s proprietary cell-culturing processes, can give rise to other cell types, such as cardiomyocyte-like and neural-like precursor cells, which could be used to treat cardiovascular and neural indications. The Company’s patented processes enables proprietary cells grown from a patient’s own blood to be injected back into that same patient’s diseased tissue in order to restore function. As previously disclosed, the Company is currently undergoing a Phase II clinical trial for critical limb ischemia (“CLI”) in Canada and the United States for its lead product ACP-01.

Having this patent awarded in the EU is significant as it provides validation in multiple countries. In addition, the EU patent is important as the European stem cell market is one of the most rapidly growing markets in the world. According to a Mordor Intelligence report entitled “Europe Stem Cell Market Growth, Trends and Forecasts (2016-2021)”, the market is currently valued at US$4.2 billion and is expected to grow at a compound annual growth rate of 15.7% over a forecast period.

“The newly granted patent covers important aspects of Hemostemix’s platform technology and this issuance strengthens our intellectual property portfolio, particularly in the EU. This provides the platform to expand our clinical trials, commercialization and partnering efforts throughout Europe.” states Dr. Ravi Jain, the Company’s Chief Scientific Officer.

“Hemostemix has now had the door opened to expand its technology and operations on a world stage. We are very excited about the opportunities that this patent will allow us to pursue, especially since the European stem cell market is significant and growing,” states Kyle Makofka, Hemostemix’s Chief Executive Officer.

The Company has a broad and growing patent portfolio which covers 5 patent families with over 50 patents issued and pending in several important jurisdictions, including the United States, Canada, Europe, Japan and China.

To download a the full press release Click Here.

View All News & Media